气喘治疗市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按药物类别、管理模式、配销通路、地区和竞争细分

全球气喘治疗市场在 2024-2028 年预测期内将出现令人印象深刻的成长。这可以归因于气喘盛行率的增加、研发活动的增加以及医疗基础设施投资的增加。气喘是许多国家的主要公共卫生问题之一，特别是在美国。此疾病的高负担产生了对有效气喘治疗的强烈需求。这导致了对开发可以预防气喘感染或减轻其严重程度的药物的大量投资。世界卫生组织 (WHO) 估计，气喘影响全球约 2.35 亿人，每年导致约 383,000 人死亡。

生物药物，也称为免疫调节剂，是一类针对参与免疫反应的特定分子的新型药物。用于气喘的生物药物的例子包括奥马珠单抗、美泊利珠单抗和贝那利珠单抗。这些药物可降低严重且不受控制的气喘患者气喘发作的频率和严重程度。人们对使用行动应用程式和穿戴式装置等数位健康技术来治疗气喘越来越感兴趣。这些工具可以帮助患者监测他们的症状，追踪他们的药物使用情况，并获得个人化的治疗建议。

政府和私人机构经常进行公众宣传活动，教育人们了解气喘的原因、症状和治疗方法。这些活动包括社交媒体活动、电视和广播广告以及宣传册和小册子等教育材料。这提高了人们的认识，并导致全球气喘治疗市场的成长。

市场概况
预测期	2024-2028
2022 年市场规模	240.1亿美元
2028 年市场规模	323.1亿美元
2023-2028 年复合年增长率	5.09%
成长最快的细分市场	吸入器
最大的市场	北美洲

私营机构可以参与宣传和游说工作，以促进支持气喘治疗和管理的政策和措施。这可以包括努力提高气喘药物的保险覆盖范围，增加气喘研究的资金，以及促进清洁空气倡议以减少气喘诱因。随着私人机构让人们意识到这会增加全球气喘市场。

哮喘盛行率增加

气喘盛行率的不断上升是全球气喘治疗市场的主要驱动力之一。气喘是一种由遗传和环境因素共同引起的慢性呼吸道疾病，透过遗传、环境因素、呼吸道感染、肥胖和压力传播给人类。 《2018 年全球气喘报告》预测，气喘将继续成为全球重大健康问题，低收入和中等收入国家的负担日益增加。报告指出，如果预防、诊断和治疗方面没有显着改善，到2030年，与气喘相关的死亡人数可能会增加20%。气喘盛行率的不断上升导致公众对该疾病的认识不断提高。这有助于减少对该疾病的耻辱感，并促进人们更好地了解有效治疗和管理的必要性。根据《2018 年全球气喘报告》，估计 2016 年全球有 3.39 亿人受到气喘影响。随着气喘盛行率的增加，越来越需要医疗基础设施来支持疾病的诊断和治疗。这可能会导致对医疗保健系统的投资增加，包括开发新的诊所、医院和其他医疗保健设施。世界卫生组织 (WHO) 报告称，近年来，全球公众对气喘的认识有所提高，这有助于减少对该疾病的耻辱感，并促进更好地了解有效治疗和管理的必要性。

提供医疗保健服务

提供医疗保健对于促进全球气喘治疗市场至关重要。气喘是一种慢性疾病，需要持续的管理和治疗，包括定期监测、药物和后续护理。无法获得医疗保健的气喘患者可能无法接受适当的治疗，这可能导致严重的併发症，例如住院、急诊室就诊，甚至死亡。根据《2018 年全球气喘报告》，2016 年气喘估计导致全球 461,000 人死亡。

获得医疗保健可以透过多种方式促进全球气喘治疗市场。首先，它可以帮助早期识别气喘患者，以便及时诊断和治疗。这可以防止更严重的气喘症状并减少紧急护理的需要。此外，医疗保健提供者可以为气喘患者提供教育和支持，帮助他们了解自己的病情并有效管理症状。在美国，估计约有 2500 万人患有气喘，其中许多人由于获得医疗保健和定期监测呼吸系统健康而在儿童时期被诊断出。

获得医疗保健可以确保气喘患者能够获得适当的药物和治疗选择。这可以包括控制症状的短期药物以及预防气喘发作的长期药物。获得医疗保健可以为气喘患者提供接触过敏症专家或肺科医生等专家的机会，他们可以提供更专业的护理和治疗。预计全球气喘治疗市场的成长。

增加研发投入

製药公司正在大力投资研发，以开发新的创新气喘治疗方法。气喘是一种复杂的疾病，需要持续的管理和治疗，并且需要新的和改进的治疗方法来解决未满足的医疗需求。美国国立卫生研究院 (NIH) 每年为气喘研究提供超过 1 亿美元的资金，支持新疗法、疾病机制和预防策略的研究。它可以帮助确定气喘的新药物标靶和治疗方案。这可能包括开发新药、生物製剂或合併疗法，为气喘患者提供更有效、更有针对性的治疗选择。

研发投资有助于提高对气喘潜在机制的了解，并确定用于诊断和监测的新生物标记。这可以实现更个人化的治疗方法，从而带来更好的结果并降低医疗成本。研发投资有助于改善气喘管理和教育，从而更好地自我管理疾病并减少医疗保健利用率。它可以包括开发用于监测和管理气喘症状的新设备和技术，以及针对医疗保健提供者和患者的教育计划。

市场区隔

全球气喘治疗市场可按药物类别、给药方式、配销通路和地区进行细分。依药物类别，全球气喘治疗市场可分为短效β受体激动剂（SABA）、长效β受体激动剂（LABA）、吸入性皮质类固醇（ICS）、白三烯调节剂、免疫调节剂、联合用药等。根据给药方式，全球气喘治疗市场分为吸入器、雾化器和口服药物。根据配销通路，全球气喘治疗市场分为医院药局、零售药局、网路药局等。从地区来看，全球气喘治疗市场可分为北美、欧洲、亚太地区、南美洲、中东和非洲。

市场参与者

GlaxoSmithKline, Plc.、AstraZeneca Plc、Teva Pharmaceutical Industries Ltd、Boehringer Ingelheim Gmbh、Merck & Co. Inc.、Novartis AG、Sanofi SA、Roche Holding AG、Regeneron Pharmaceutical Inc、Pfizer Inc. 是全球营运的一些领先企业气喘治疗市场。

报告范围：

在本报告中，除了以下详细介绍的产业趋势外，全球气喘治疗市场也分为以下几类：

气喘治疗市场，依药物类型：

• 短效 β 激动剂 (SABA)
• 长效 β 受体激动剂 (LABA)
• 吸入性皮质类固醇 (ICS)
• 白三烯调节剂
• 免疫调节剂
• 复方药物
• 其他的

气喘治疗市场，依管理模式划分：

• 吸入器
• 雾化器
• 口服药物
• 气喘治疗市场，按配销通路
• 医院药房
• 零售药局
• 网路药局
• 其他的

气喘治疗市场，按地区：

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 德国
• 英国
• 法国
• 义大利
• 西班牙
• 亚太地区
• 印度
• 日本
• 韩国
• 澳洲
• 中国
• 南美洲
• 巴西
• 哥伦比亚
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿联酋

竞争格局

• 公司简介：全球气喘治疗市场主要公司的详细分析。

可用的客製化：

• 根据给定的市场资料，TechSci Research 可根据公司的具体需求提供客製化服务。该报告可以使用以下自订选项：

公司资讯

• 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 涵盖的市场
  • 考虑学习的年份
  • 主要市场区隔

第 2 章：研究方法

• 研究目的
• 基线方法
• 主要产业伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量与验证
• 假设和限制

第 3 章：执行摘要

• 市场概况
• 主要市场细分概述
• 主要市场参与者概述
• 重点地区/国家概况
• 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球气喘治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依药物类别（短效 β 受体激动剂 (SABA)、长效 β 受体激动剂 (LABA)、吸入性皮质类固醇 (ICS)、白三烯调节剂、免疫调节剂、组合药物、其他）
  • 依给药方式（吸入器、雾化器、口服药物）
  • 按配销通路（医院药房、零售药房、网路药房、其他）
  • 按地区
  • 按公司划分 (2022)
• 产品图
  • 按药物类别
  • 按管理方式
  • 按配销通路

第 6 章：北美气喘治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物类别
  • 按管理方式
  • 按配销通路
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 7 章：欧洲气喘治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物类别
  • 按管理方式
  • 按配销通路
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太地区气喘治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物类别
  • 按管理方式
  • 按配销通路
  • 按国家/地区
• 亚太地区：国家分析
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲气喘治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物类别
  • 按管理方式
  • 按配销通路
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲气喘治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物类别
  • 按管理方式
  • 按配销通路
  • 按国家/地区
• MEA：国家分析
  • 南非气喘治疗
  • 沙乌地阿拉伯气喘治疗
  • 阿联酋气喘治疗

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 13 章：全球气喘治疗市场：SWOT 分析

第 14 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第15章：竞争格局

• 商业概览
• 产品供应
• 最近的发展
• 主要人员
• SWOT分析
  • GlaxoSmithKline, Plc.
  • AstraZeneca Plc
  • Teva Pharmaceutical Industries Ltd
  • Boehringer Ingelheim Gmbh
  • Merck & Co. Inc
  • Novartis AG
  • Sanofi SA
  • Roche Holding AG
  • Regeneron Pharmaceutical Inc
  • Pfizer Inc.

第 16 章：策略建议

Global asthma treatment market will witness an impressive growth during the forecast period, 2024-2028. This can be ascribed to the increasing prevalence of asthma, growing R&D activities and increasing investment in healthcare infrastructure. Asthma is one of the major public health problem in many countries, particularly in the United States. The high burden of the disease has created a strong demand for effective Asthma Treatment. This has led to significant investment in the development of medications that can prevent Asthma Infection or reduce its severity. The World Health Organization (WHO) estimates that asthma affects around 235 million people worldwide and is responsible for approximately 383,000 deaths annually.

Biologic medications, also known as immunomodulators, are a new class of drugs that target specific molecules involved in the immune response. Examples of biologic medications used for asthma include omalizumab, mepolizumab, and benralizumab. These medications reduce the frequency and severity of asthma exacerbations in patients with severe, uncontrolled asthma. There is growing interest in the use of digital health technologies, such as mobile apps and wearable devices, for the management of asthma. These tools may help patients to monitor their symptoms, track their medication use, and receive personalized treatment recommendations.

Governments and private agencies often run public awareness campaigns to educate people about the causes, symptoms, and treatment of asthma. These campaigns include social media campaigns, television and radio ads, and educational materials such as brochures and pamphlets. This increases awareness among people and results in the growth of global asthma treatment market.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD24.01 Billion
Market Size 2028	USD32.31 Billion
CAGR 2023-2028	5.09%
Fastest Growing Segment	Inhalers
Largest Market	North America

Private agencies may engage in advocacy and lobbying efforts to promote policies and initiatives that support asthma treatment and management. This can include efforts to improve insurance coverage for asthma medications, increase funding for asthma research, and promote clean air initiatives to reduce asthma triggers. As the private agencies make people aware this increases the global asthma market.

Increasing Prevalence of Asthma

The growing prevalence of asthma is one of the key drivers of the global asthma treatment market. Asthma is a chronic respiratory condition that is caused by a combination of genetic and environmental factors, which is transmitted to humans through genetics, environmental factors, respiratory infection, obesity, and stress. Global Asthma Report 2018 predicts that asthma will continue to be a significant global health concern, with an increasing burden in low- and middle-income countries. The report notes that without significant improvements in prevention, diagnosis, and treatment, the number of asthma-related deaths may increase by 20% by 2030. The growing prevalence of asthma has led to increased public awareness of the condition. This has helped to reduce stigma around the condition and promote better understanding of the need for effective treatment and management. According to Global Asthma Report 2018, an estimated 339 million people worldwide were affected by asthma in 2016. As the prevalence of asthma increases, there is a greater need for healthcare infrastructure to support the diagnosis and treatment of the condition. This can lead to increased investment in healthcare systems, including the development of new clinics, hospitals, and other healthcare facilities. The World Health Organization (WHO) reports that there has been an increase in public awareness about asthma globally in recent years, which has helped to reduce stigma around the condition and promote better understanding of the need for effective treatment and management.

The growing prevalence of asthma drives research and development in the field of asthma treatment. As more people are diagnosed with asthma, there is a greater need for new and more effective treatments to manage the condition.

Providing Access to Healthcare

Providing access to healthcare is essential for promoting the global asthma treatment market. Asthma is a chronic condition that requires ongoing management and treatment, including regular monitoring, medication, and follow-up care. People with asthma who do not have access to healthcare may not receive appropriate treatment, which can lead to serious complications, such as hospitalization, emergency room visits, and even death. According to the Global Asthma Report 2018, asthma is estimated to have caused 461,000 deaths globally in 2016.

Access to healthcare can promote the global asthma treatment market in several ways. Firstly, it can help to identify people with asthma early, allowing for prompt diagnosis and treatment. This can prevent the development of more severe asthma symptoms and reduce the need for emergency care. Additionally, healthcare providers can provide education and support people with asthma, helping them to understand their condition and manage their symptoms effectively. In the United States, it is estimated that around 25 million people have asthma, and many of these are diagnosed in childhood due to access to healthcare and regular monitoring of respiratory health.

Access to healthcare can ensure that people with asthma have access to appropriate medications and treatment options. This can include both short-term medications to manage symptoms as well as long-term medications to prevent asthma attacks from occurring. Access to healthcare can provide people with asthma with the access to specialists, such as allergists or pulmonologists, who can provide more specialized care and treatment. anticipated in the growth of global asthma treatment market.

Increasing Investment in Research and Development

Pharmaceutical companies are investing heavily in research and development to develop new and innovative asthma treatments. Asthma is a complex disease that requires ongoing management and treatment, and there is a need for new and improved treatments to address unmet medical needs. The National Institutes of Health (NIH) in the United States provides over USD 100 million in funding for asthma research each year, supporting research into new treatments, disease mechanisms, and prevention strategies. It can help to identify new drug targets and treatment options for asthma. This can include the development of novel drugs, biologics, or combination therapies that may provide more effective and targeted treatment options for people with asthma.

Investment in R&D can help to improve the understanding of the underlying mechanisms of asthma and identify new biomarkers for diagnosis and monitoring. This can enable more personalized treatment approaches, which may lead to better outcomes and reduced healthcare costs. Investment in R&D can help to improve asthma management and education, leading to better self-management of the disease and reduced healthcare utilization. It can include the development of new devices and technologies for monitoring and managing asthma symptoms, as well as education programs for healthcare providers and patients.

Market Segmentation

Global asthma treatment market can be segmented by drug class, mode of administration, distribution channel, and region. Based on drug class, global asthma treatment market can be divided into short-acting beta-agonists (SABA), long-acting beta-agonists (LABA), inhaled corticosteroids (ICS), leukotriene modifiers, immunomodulators, combination drugs, and others. Based on mode of administration, the global asthma treatment market is divided into inhalers, nebulizers, and oral medications. Based on distribution channel, the global asthma treatment market is divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. Regionally, the global asthma treatment market can be categorized into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

GlaxoSmithKline, Plc., AstraZeneca Plc, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim Gmbh, Merck & Co. Inc, Novartis AG, Sanofi SA, Roche Holding AG, Regeneron Pharmaceutical Inc, Pfizer Inc. are some of the leading players operating in the global asthma treatment market.

Report Scope:

In this report, global asthma treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Asthma Treatment Market, By Drug Type:

• Short Acting Beta-Agonists (SABA)
• Long-Acting Beta-Agonists (LABA)
• Inhaled Corticosteroids (ICS)
• Leukotriene Modifiers
• Immunomodulator
• Combination Drugs
• Others

Asthma Treatment Market, By Mode of Administration:

• Inhalers
• Nebulizers
• Oral Medications
• Asthma treatment Market, By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Asthma Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Asia Pacific
• India
• Japan
• South Korea
• Australia
• China
• South America
• Brazil
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in global asthma treatment market.

Available Customizations:

• With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Asthma Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Short acting beta-agonists (SABA), Long-acting beta-agonists (LABA), Inhaled corticosteroids (ICS), Leukotriene modifiers, Immunomodulators, Combination drugs, Others)
  • 5.2.2. By Mode Of Administration (Inhalers, Nebulizers, Oral medications)
  • 5.2.3. By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Product Map
  • 5.3.1. By Drug Class
  • 5.3.2. By Mode of Administration
  • 5.3.3. By Distribution Channel

6. North America Asthma Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Mode of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Asthma Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Mode of Administration
      • 6.3.1.2.3. Distribution Channel
  • 6.3.2. Canada Asthma Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Mode of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Asthma Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Mode of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Asthma Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Mode of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Asthma Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Mode of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Asthma Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Mode of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Asthma Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Mode of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Asthma Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Mode of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Asthma Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Mode of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Asthma Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Mode of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. India Asthma Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Mode of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Japan Asthma Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Mode of Administration
      • 8.3.2.2.3. By distribution Channel
  • 8.3.3. South Korea Asthma Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Mode of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Australia Asthma Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Mode of Administration
      • 8.3.4.2.3. By Distribution Channel

9. South America Asthma Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Mode of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Asthma Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Mode of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Asthma Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Mode of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Asthma Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Mode of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Asthma Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Mode of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Asthma Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Mode of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Asthma Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Mode of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Asthma Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Mode of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Asthma Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Product Offerings
• 15.3. Recent Developments
• 15.4. Key Personnel
• 15.5. SWOT Analysis
  • 15.5.1. GlaxoSmithKline, Plc.
  • 15.5.2. AstraZeneca Plc
  • 15.5.3. Teva Pharmaceutical Industries Ltd
  • 15.5.4. Boehringer Ingelheim Gmbh
  • 15.5.5. Merck & Co. Inc
  • 15.5.6. Novartis AG
  • 15.5.7. Sanofi SA
  • 15.5.8. Roche Holding AG
  • 15.5.9. Regeneron Pharmaceutical Inc
  • 15.5.10. Pfizer Inc.

16. Strategic Recommendations